1
|
Schaefer E, Demmelmair H, Horak J, Holdt L, Grote V, Maar K, Neuhofer C, Teupser D, Thiel N, Goeckeler-Leopold E, Maggini S, Koletzko B. Multiple Micronutrients, Lutein, and Docosahexaenoic Acid Supplementation during Lactation: A Randomized Controlled Trial. Nutrients 2020; 12:E3849. [PMID: 33339438 PMCID: PMC7765837 DOI: 10.3390/nu12123849] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 12/10/2020] [Accepted: 12/14/2020] [Indexed: 01/28/2023] Open
Abstract
Breastfed infants require an adequate supply of critical nutrients for growth, tissue functions, and health. Recommended intakes for several nutrients are considerably higher in lactating than non-lactating women but are not always met with habitual diets. We report a randomized, double-blind clinical trial in 70 healthy lactating women in Germany evaluating the effects of supplementation with multiple micronutrients, lutein, and docosahexaenoic acid (DHA) compared to placebo on maternal nutrient status and milk composition. The primary endpoint was the effect on the change of human milk DHA content (as a proportion of total milk fatty acids) during 12 weeks of supplementation. Maternal blood and milk biomarkers were measured as secondary endpoints. Supplementation increased maternal milk DHA by 30% compared to a decline in the placebo group. Supplementation also increased maternal blood DHA (17%), eicosapentaenoic acid (4%), 25-OH-vitamin D (24%), vitamin B12 (12%), lutein (4%), and beta carotene (49%), while homocysteine decreased. No significant difference in the number of adverse events was observed between supplementation and placebo groups. In conclusion, multi-micronutrient supplementation was safe and increased maternal blood and milk concentrations of selected nutrients in healthy women.
Collapse
Affiliation(s)
- Ella Schaefer
- Bayer Consumer Care AG, Peter-Merian-Straße 84, 4002 Basel, Switzerland;
| | - Hans Demmelmair
- Department Paediatrics, Division Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Lindwurmstraße 4, 80337 Munich, Germany; (H.D.); (J.H.); (V.G.); (B.K.)
| | - Jeannie Horak
- Department Paediatrics, Division Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Lindwurmstraße 4, 80337 Munich, Germany; (H.D.); (J.H.); (V.G.); (B.K.)
| | - Lesca Holdt
- Institute of Laboratory Medicine, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Marchioninistraße 15, 81377 Munich, Germany; (L.H.); (D.T.)
| | - Veit Grote
- Department Paediatrics, Division Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Lindwurmstraße 4, 80337 Munich, Germany; (H.D.); (J.H.); (V.G.); (B.K.)
| | - Karoline Maar
- Gynecology & Obstetrics Specialist, Schloßstraße 2, 13507 Berlin, Germany;
| | - Christoph Neuhofer
- Gynecology & Obstetrics Specialist, Marienplatz 4, 85354 Freising, Germany; (C.N.); (N.T.)
| | - Daniel Teupser
- Institute of Laboratory Medicine, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Marchioninistraße 15, 81377 Munich, Germany; (L.H.); (D.T.)
| | - Nadja Thiel
- Gynecology & Obstetrics Specialist, Marienplatz 4, 85354 Freising, Germany; (C.N.); (N.T.)
| | | | - Silvia Maggini
- Bayer Consumer Care AG, Peter-Merian-Straße 84, 4002 Basel, Switzerland;
| | - Berthold Koletzko
- Department Paediatrics, Division Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, LMU University Hospitals, Ludwig-Maximilians-Universität Munich, Lindwurmstraße 4, 80337 Munich, Germany; (H.D.); (J.H.); (V.G.); (B.K.)
| |
Collapse
|
2
|
Oudijk L, Neuhofer C, Lichtenauer UD, Papathomas TG, Korpershoek E, Stoop H, Oosterhuis JW, Smid M, Restuccia DF, Robledo M, de Cubas A, Mannelli M, Gimenez-Roqueplo AP, Dinjens WNM, Beuschlein F, de Krijger RR. Characterization of Stem Cell Markers in Pheochromocytomas and Paragangliomas. Exp Clin Endocrinol Diabetes 2014. [DOI: 10.1055/s-0034-1372312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Jacobs VR, Neuhofer C, Schwarz-Boeger U, Schaaf H, Kiechle M. Technische Entwicklung und klinische Erprobung eines dünneren, flexiblen Mikrohysteroskopes mit abwinkelbarer Optik zur gezielten Biopsie des Endometriums unter Sicht. Geburtshilfe Frauenheilkd 2003. [DOI: 10.1055/s-2003-815227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Bremer M, Neuhofer C, Auberger T, Zimmermann FB, Kneschaurek P, Reuschel W, Molls M. Palliative radiotherapy of malignant melanoma with reactor fission neutron therapy (RENT): a prospective study. Radiat Oncol Investig 1999; 7:118-24. [PMID: 10333253 DOI: 10.1002/(sici)1520-6823(1999)7:2<118::aid-roi8>3.0.co;2-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To study the efficacy and safety of relatively low-dosed reactor fission neutron therapy (RENT) at the research reactor of the Technical University Munich, we treated 33 superficial lesions of 20 patients with advanced malignant melanoma by neutron beam alone (n = 22), mixed neutron/electron beam (n = 5), or by neutron beam after incomplete surgery (n = 6). Median tumor volume was 17.0 cm3. Median dose for neutron beam alone was 8.0 Gy and for mixed beam 3.0 Gy n + 45.3 Gy e-. Local tumor response, local control time, survival and treatment related toxicity were followed prospectively over a time period of 52 months. Overall response rate (CR;PR) after neutron beam alone and mixed beam therapy was 64% (CR: 36%) and 100% (CR: 60%), respectively. Observed differences between complete (CR) and incomplete (PR, NC) responding lesions were as follows: median tumor volume: 2.0 vs. 51.5 cm3, local control time: 13.3 vs. 3.7 months, median survival: 19.8 vs. 9.0 months. No severe acute or late sequelae could be observed. In conclusion, low-dosed RENT is an effective and well tolerated palliative treatment of superficial malignant melanoma utilizing the biologic advantage of diminished cellular repair capacity. Because melanoma lesions of small size (< or = 6 cm3) tend to respond completely, neutron beam should be performed at an early stage.
Collapse
Affiliation(s)
- M Bremer
- Department of Radiation Oncology, Technical University Munich, Germany.
| | | | | | | | | | | | | |
Collapse
|